Is Labcorp Holdings (LH) Stock Above Fair Value After Two Deals?

Labcorp Holdings has delivered a solid share price run in recent years, which puts more focus on whether the current valuation is properly backed by its cash flows. With the stock now reflecting both steady share gains and fresh deal activity, the key question is how much of its future cash generation is already factored into today's price.

• Over the past 3 years, Labcorp Holdings has returned 65.9%, so a lot of investor expectations now rest on the durability and growth of its future cash flows.
• Recent agreements to acquire Myriad Genetics' Prenatal Health testing business and select assets of BioReference Health can reshape Labcorp Holdings' mix of diagnostic services, which may influence both cash-flow timing and the reinvestment needed to integrate these operations.
• Prefer to judge Labcorp Holdings on earnings? See what Labcorp Holdings's 26.7x P/E says about the price.

The issue now is whether Labcorp Holdings' current share price is adequately supported by the cash flows implied by its Discounted Cash Flow (DCF) intrinsic value estimate.

To pressure test whether Labcorp Holdings' recent 65.9% three year return is fairly grounded in its cash flows, it can help to compare against solid balance sheet and fundamentals stocks screener (26 results).

Is Labcorp Holdings Fairly Priced on Cash Flow?

The Discounted Cash Flow (DCF) approach here focuses on the cash Labcorp Holdings can return to shareholders over time. Latest twelve month free cash flow sits at about $1.12b, with the model assuming future free cash flow that softens near term to $908.55m in 2024 then trends into relatively steady projections through the early 2030s. Those inputs point to a business that the model treats as mature, with moderate adjustments rather than aggressive expansion included in the forecast.

On that basis, the DCF output suggests Labcorp Holdings is broadly in line with the current share price of $329.93. The planned acquisitions of Myriad Genetics' Prenatal Health testing unit and select BioReference Health assets help explain why the market is willing to pay for consistency in cash generation, despite the integration work that comes with those deals. The full cash flow breakdown, and how it maps to the implied intrinsic value range versus today's price, sits in the detailed model output. Find out what Labcorp Holdings could be worth using our Discounted Cash Flow (DCF) estimate.

The Labcorp Holdings Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the DCF puzzle for Labcorp Holdings leaves off. They spell out in plain terms what kinds of growth, margins and earnings paths would need to play out for the shares to be worth meaningfully more or less than today’s price. Each one treats Labcorp Holdings' fair value as a thesis about how the business develops over time, which you can revisit later to see how the reasoning holds up, and they sit on the company’s Community page.

One of the top community narratives on Labcorp Holdings: roughly fairly valued

"Analysts expect Labcorp Holdings to keep building on higher value specialty testing and biopharma central lab work as key operational focus areas..."

Discover why this Narrative puts Labcorp Holdings at roughly fairly valued.

One last check for Labcorp Holdings before you stop at the share price

Cash flows and valuation models only go so far if the people in charge have misaligned priorities, so it pays to see who is steering Labcorp Holdings and how their incentives are structured. See who runs Labcorp Holdings and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com